Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer

Gustavo Ayala, Takefumi Satoh, Rile Li, Moshe Shalev, Yehoshua Gdor, Estuardo Aguilar-Cordova, Anna Frolov, Thomas M. Wheeler, Brian J. Miles, Katherine A Rauen, Bin S. Teh, Brian E. Butler, Timothy C. Thompson, Dov Kadmon

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The limitations of current forms of prostate cancer therapy have driven researchers to search for new alternatives. Previously we showed cytopathic effect related to HSV-tk in prostate cancer. In this study we present initial results of a neoadjuvant HSV-tk gene therapy trial and address some of the potential mechanistic aspects of its effect in human tissues. We enrolled 23 men with clinically localized prostate cancer but high risk for recurrence in this Phase I-II trial. Intraprostatic viral injections (one to four) were followed by 2 weeks of ganciclovir and prostatectomy 2-4 weeks later. Toxicity was modest. Surgical specimens were embedded fully and whole-mount slides were imaged and analyzed for areas of cytopathic effect. The larger the tumor the greater the cytopathic effect. The effect also seems to be related to areas of high CAR expression. However, the number of injection sites did not influence effect. Local (CD8+ cells and macrophages) and systemic immune response (CD8+ and activated CD8+, IL-12) was increased in patients treated with HSV-tk. Increased apoptosis and decreased microvessel density were also noted in these patients. The results suggest a tumor-specific effect mediated by systemic and local immune response, antiangiogenic effect, and modulation of apoptosis.

Original languageEnglish (US)
Pages (from-to)716-728
Number of pages13
JournalMolecular Therapy
Volume13
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Ganciclovir
Genetic Therapy
Prostatic Neoplasms
Apoptosis
Injections
Interleukin-12
Prostatectomy
Microvessels
Neoplasms
Macrophages
Research Personnel
Recurrence
Therapeutics

Keywords

  • Apoptosis
  • Car
  • Gene therapy
  • HSV-tk
  • Immune response
  • Microvessel density
  • Necrosis
  • Prostate cancer

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Ayala, G., Satoh, T., Li, R., Shalev, M., Gdor, Y., Aguilar-Cordova, E., ... Kadmon, D. (2006). Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Molecular Therapy, 13(4), 716-728. https://doi.org/10.1016/j.ymthe.2005.11.022

Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. / Ayala, Gustavo; Satoh, Takefumi; Li, Rile; Shalev, Moshe; Gdor, Yehoshua; Aguilar-Cordova, Estuardo; Frolov, Anna; Wheeler, Thomas M.; Miles, Brian J.; Rauen, Katherine A; Teh, Bin S.; Butler, Brian E.; Thompson, Timothy C.; Kadmon, Dov.

In: Molecular Therapy, Vol. 13, No. 4, 04.2006, p. 716-728.

Research output: Contribution to journalArticle

Ayala, G, Satoh, T, Li, R, Shalev, M, Gdor, Y, Aguilar-Cordova, E, Frolov, A, Wheeler, TM, Miles, BJ, Rauen, KA, Teh, BS, Butler, BE, Thompson, TC & Kadmon, D 2006, 'Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer', Molecular Therapy, vol. 13, no. 4, pp. 716-728. https://doi.org/10.1016/j.ymthe.2005.11.022
Ayala, Gustavo ; Satoh, Takefumi ; Li, Rile ; Shalev, Moshe ; Gdor, Yehoshua ; Aguilar-Cordova, Estuardo ; Frolov, Anna ; Wheeler, Thomas M. ; Miles, Brian J. ; Rauen, Katherine A ; Teh, Bin S. ; Butler, Brian E. ; Thompson, Timothy C. ; Kadmon, Dov. / Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. In: Molecular Therapy. 2006 ; Vol. 13, No. 4. pp. 716-728.
@article{31fbd0a597a748588d8ebf26fe97ec7c,
title = "Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer",
abstract = "The limitations of current forms of prostate cancer therapy have driven researchers to search for new alternatives. Previously we showed cytopathic effect related to HSV-tk in prostate cancer. In this study we present initial results of a neoadjuvant HSV-tk gene therapy trial and address some of the potential mechanistic aspects of its effect in human tissues. We enrolled 23 men with clinically localized prostate cancer but high risk for recurrence in this Phase I-II trial. Intraprostatic viral injections (one to four) were followed by 2 weeks of ganciclovir and prostatectomy 2-4 weeks later. Toxicity was modest. Surgical specimens were embedded fully and whole-mount slides were imaged and analyzed for areas of cytopathic effect. The larger the tumor the greater the cytopathic effect. The effect also seems to be related to areas of high CAR expression. However, the number of injection sites did not influence effect. Local (CD8+ cells and macrophages) and systemic immune response (CD8+ and activated CD8+, IL-12) was increased in patients treated with HSV-tk. Increased apoptosis and decreased microvessel density were also noted in these patients. The results suggest a tumor-specific effect mediated by systemic and local immune response, antiangiogenic effect, and modulation of apoptosis.",
keywords = "Apoptosis, Car, Gene therapy, HSV-tk, Immune response, Microvessel density, Necrosis, Prostate cancer",
author = "Gustavo Ayala and Takefumi Satoh and Rile Li and Moshe Shalev and Yehoshua Gdor and Estuardo Aguilar-Cordova and Anna Frolov and Wheeler, {Thomas M.} and Miles, {Brian J.} and Rauen, {Katherine A} and Teh, {Bin S.} and Butler, {Brian E.} and Thompson, {Timothy C.} and Dov Kadmon",
year = "2006",
month = "4",
doi = "10.1016/j.ymthe.2005.11.022",
language = "English (US)",
volume = "13",
pages = "716--728",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer

AU - Ayala, Gustavo

AU - Satoh, Takefumi

AU - Li, Rile

AU - Shalev, Moshe

AU - Gdor, Yehoshua

AU - Aguilar-Cordova, Estuardo

AU - Frolov, Anna

AU - Wheeler, Thomas M.

AU - Miles, Brian J.

AU - Rauen, Katherine A

AU - Teh, Bin S.

AU - Butler, Brian E.

AU - Thompson, Timothy C.

AU - Kadmon, Dov

PY - 2006/4

Y1 - 2006/4

N2 - The limitations of current forms of prostate cancer therapy have driven researchers to search for new alternatives. Previously we showed cytopathic effect related to HSV-tk in prostate cancer. In this study we present initial results of a neoadjuvant HSV-tk gene therapy trial and address some of the potential mechanistic aspects of its effect in human tissues. We enrolled 23 men with clinically localized prostate cancer but high risk for recurrence in this Phase I-II trial. Intraprostatic viral injections (one to four) were followed by 2 weeks of ganciclovir and prostatectomy 2-4 weeks later. Toxicity was modest. Surgical specimens were embedded fully and whole-mount slides were imaged and analyzed for areas of cytopathic effect. The larger the tumor the greater the cytopathic effect. The effect also seems to be related to areas of high CAR expression. However, the number of injection sites did not influence effect. Local (CD8+ cells and macrophages) and systemic immune response (CD8+ and activated CD8+, IL-12) was increased in patients treated with HSV-tk. Increased apoptosis and decreased microvessel density were also noted in these patients. The results suggest a tumor-specific effect mediated by systemic and local immune response, antiangiogenic effect, and modulation of apoptosis.

AB - The limitations of current forms of prostate cancer therapy have driven researchers to search for new alternatives. Previously we showed cytopathic effect related to HSV-tk in prostate cancer. In this study we present initial results of a neoadjuvant HSV-tk gene therapy trial and address some of the potential mechanistic aspects of its effect in human tissues. We enrolled 23 men with clinically localized prostate cancer but high risk for recurrence in this Phase I-II trial. Intraprostatic viral injections (one to four) were followed by 2 weeks of ganciclovir and prostatectomy 2-4 weeks later. Toxicity was modest. Surgical specimens were embedded fully and whole-mount slides were imaged and analyzed for areas of cytopathic effect. The larger the tumor the greater the cytopathic effect. The effect also seems to be related to areas of high CAR expression. However, the number of injection sites did not influence effect. Local (CD8+ cells and macrophages) and systemic immune response (CD8+ and activated CD8+, IL-12) was increased in patients treated with HSV-tk. Increased apoptosis and decreased microvessel density were also noted in these patients. The results suggest a tumor-specific effect mediated by systemic and local immune response, antiangiogenic effect, and modulation of apoptosis.

KW - Apoptosis

KW - Car

KW - Gene therapy

KW - HSV-tk

KW - Immune response

KW - Microvessel density

KW - Necrosis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=33645510632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645510632&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2005.11.022

DO - 10.1016/j.ymthe.2005.11.022

M3 - Article

C2 - 16480930

AN - SCOPUS:33645510632

VL - 13

SP - 716

EP - 728

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -